Cargando…

Vaccine safety surveillance informs public health policy beyond immunization: A case-series on bleeding following vaccination, Nepal, 2016–2018

BACKGROUND: Surveillance for adverse events following immunization (AEFI) is important to monitor vaccine safety and should lead to appropriate responses to improve health and immunization program. Bleeding following vaccination is not recognized as an important AEFI. Without policy of vitamin K (VK...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradhan, Rahul, Sharma Gautam, Jhalak, Tinkari, Bhim Singh, Adhikari, Neelam, Bose, Anindya Sekhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482439/
https://www.ncbi.nlm.nih.gov/pubmed/32788134
http://dx.doi.org/10.1016/j.vaccine.2020.07.035
_version_ 1783580789098676224
author Pradhan, Rahul
Sharma Gautam, Jhalak
Tinkari, Bhim Singh
Adhikari, Neelam
Bose, Anindya Sekhar
author_facet Pradhan, Rahul
Sharma Gautam, Jhalak
Tinkari, Bhim Singh
Adhikari, Neelam
Bose, Anindya Sekhar
author_sort Pradhan, Rahul
collection PubMed
description BACKGROUND: Surveillance for adverse events following immunization (AEFI) is important to monitor vaccine safety and should lead to appropriate responses to improve health and immunization program. Bleeding following vaccination is not recognized as an important AEFI. Without policy of vitamin K (VK) prophylaxis at birth, vitamin K deficiency bleeding (VKDB) could be an important cause of bleeding in young infants and may manifest as AEFI. METHODS: We retrospectively analysed all serious AEFI cases that presented with external or internal bleeding reported to Nepal’s AEFI surveillance system during 2016–2018. The cases were classified as VKDB, suspected VKDB or non-VKDB. RESULTS: During the period, 16 serious AEFI with symptom or sign of bleeding were reported representing 21.3% of all serious AEFI reported. Cases were between 40 and 94 days of age. The National AEFI Investigation Committee classified all cases as coincidental. Fourteen cases (87.5%) had bleeding from injection site. Median time from vaccination to injection site bleeding was 4.3 h (interquartile range: 2.1–11.6 h). Six cases (37.5%) had intra-cranial haemorrhage. Only one case had confirmed history of receiving VK at birth. Ten cases (62.5%) received appropriate treatment (VK injection; blood transfusion if needed). Based on limited laboratory investigations available, three cases (18.75%) could be classified as late onset VKDB and 11 cases (68.75%) as suspected late onset VKDB. CONCLUSION: VKDB should be suspected in young infants presenting with bleeding including following vaccination, and prompt treatment should be initiated. Bleeding following vaccination should be recognized as an important AEFI as even a small amount of blood loss in young infants can be catastrophic. We posit that this series is a small subset of VKDB cases in Nepal detected through AEFI surveillance system. In countries without policy of VK prophylaxis at birth including Nepal, the policy should be introduced.
format Online
Article
Text
id pubmed-7482439
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-74824392020-09-17 Vaccine safety surveillance informs public health policy beyond immunization: A case-series on bleeding following vaccination, Nepal, 2016–2018 Pradhan, Rahul Sharma Gautam, Jhalak Tinkari, Bhim Singh Adhikari, Neelam Bose, Anindya Sekhar Vaccine Article BACKGROUND: Surveillance for adverse events following immunization (AEFI) is important to monitor vaccine safety and should lead to appropriate responses to improve health and immunization program. Bleeding following vaccination is not recognized as an important AEFI. Without policy of vitamin K (VK) prophylaxis at birth, vitamin K deficiency bleeding (VKDB) could be an important cause of bleeding in young infants and may manifest as AEFI. METHODS: We retrospectively analysed all serious AEFI cases that presented with external or internal bleeding reported to Nepal’s AEFI surveillance system during 2016–2018. The cases were classified as VKDB, suspected VKDB or non-VKDB. RESULTS: During the period, 16 serious AEFI with symptom or sign of bleeding were reported representing 21.3% of all serious AEFI reported. Cases were between 40 and 94 days of age. The National AEFI Investigation Committee classified all cases as coincidental. Fourteen cases (87.5%) had bleeding from injection site. Median time from vaccination to injection site bleeding was 4.3 h (interquartile range: 2.1–11.6 h). Six cases (37.5%) had intra-cranial haemorrhage. Only one case had confirmed history of receiving VK at birth. Ten cases (62.5%) received appropriate treatment (VK injection; blood transfusion if needed). Based on limited laboratory investigations available, three cases (18.75%) could be classified as late onset VKDB and 11 cases (68.75%) as suspected late onset VKDB. CONCLUSION: VKDB should be suspected in young infants presenting with bleeding including following vaccination, and prompt treatment should be initiated. Bleeding following vaccination should be recognized as an important AEFI as even a small amount of blood loss in young infants can be catastrophic. We posit that this series is a small subset of VKDB cases in Nepal detected through AEFI surveillance system. In countries without policy of VK prophylaxis at birth including Nepal, the policy should be introduced. Elsevier Science 2020-09-11 /pmc/articles/PMC7482439/ /pubmed/32788134 http://dx.doi.org/10.1016/j.vaccine.2020.07.035 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Article
Pradhan, Rahul
Sharma Gautam, Jhalak
Tinkari, Bhim Singh
Adhikari, Neelam
Bose, Anindya Sekhar
Vaccine safety surveillance informs public health policy beyond immunization: A case-series on bleeding following vaccination, Nepal, 2016–2018
title Vaccine safety surveillance informs public health policy beyond immunization: A case-series on bleeding following vaccination, Nepal, 2016–2018
title_full Vaccine safety surveillance informs public health policy beyond immunization: A case-series on bleeding following vaccination, Nepal, 2016–2018
title_fullStr Vaccine safety surveillance informs public health policy beyond immunization: A case-series on bleeding following vaccination, Nepal, 2016–2018
title_full_unstemmed Vaccine safety surveillance informs public health policy beyond immunization: A case-series on bleeding following vaccination, Nepal, 2016–2018
title_short Vaccine safety surveillance informs public health policy beyond immunization: A case-series on bleeding following vaccination, Nepal, 2016–2018
title_sort vaccine safety surveillance informs public health policy beyond immunization: a case-series on bleeding following vaccination, nepal, 2016–2018
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482439/
https://www.ncbi.nlm.nih.gov/pubmed/32788134
http://dx.doi.org/10.1016/j.vaccine.2020.07.035
work_keys_str_mv AT pradhanrahul vaccinesafetysurveillanceinformspublichealthpolicybeyondimmunizationacaseseriesonbleedingfollowingvaccinationnepal20162018
AT sharmagautamjhalak vaccinesafetysurveillanceinformspublichealthpolicybeyondimmunizationacaseseriesonbleedingfollowingvaccinationnepal20162018
AT tinkaribhimsingh vaccinesafetysurveillanceinformspublichealthpolicybeyondimmunizationacaseseriesonbleedingfollowingvaccinationnepal20162018
AT adhikarineelam vaccinesafetysurveillanceinformspublichealthpolicybeyondimmunizationacaseseriesonbleedingfollowingvaccinationnepal20162018
AT boseanindyasekhar vaccinesafetysurveillanceinformspublichealthpolicybeyondimmunizationacaseseriesonbleedingfollowingvaccinationnepal20162018